Patents by Inventor Luke UTLEY

Luke UTLEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL TEBIPENEM PIVOXIL IMMEDIATE AND MODIFIED RELEASE ORAL DOSAGE FORMS
    Publication number: 20200016126
    Abstract: Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.
    Type: Application
    Filed: December 15, 2017
    Publication date: January 16, 2020
    Inventors: Akash JAIN, Enxian LU, Shaoqiong LYU, Shoufeng LI, Timothy KEUTZER, Luke UTLEY, Grayzyna FRACZKIEWICZ, Joyce MACWAN
  • N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
    Patent number: 10111878
    Abstract: Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: October 30, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jeremy Travins, Luke Utley
  • N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20170348318
    Abstract: Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.
    Type: Application
    Filed: June 22, 2017
    Publication date: December 7, 2017
    Inventors: Jeremy Travins, Luke Utley
  • N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
    Patent number: 9724350
    Abstract: Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 8, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jeremy Travins, Luke Utley
  • N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20160158241
    Abstract: Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.
    Type: Application
    Filed: July 10, 2014
    Publication date: June 9, 2016
    Inventors: Jeremy TRAVINS, Luke UTLEY